Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02290431 · OUTCOME

Overall Survival (OS)

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2019-11-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
up to 30 days after end of study, approx. 4 years

What was measured

OS is defined as time from first dose of study treatment to death

Analysis population: FAS: The FAS comprised of all subjects who took at least one dose of any study treatment component.

Groups in this outcome

LBH589 + Bortezomib + Dexamethasone

Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
LBH589 + Bortezomib + Dexamethasone31

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
LBH589 + Bortezomib + DexamethasoneNANot reportedNANAN/A = not estimable as most of the participants were still alive and censored.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        N/A = not estimable as most of the participants were still alive and censored.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    units
    Participants
description
OS is defined as time from first dose of study treatment to death
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.
    id
    OG000
    title
    LBH589 + Bortezomib + Dexamethasone
param Type
MEDIAN
population Description
FAS: The FAS comprised of all subjects who took at least one dose of any study treatment component.
reporting Status
POSTED
time Frame
up to 30 days after end of study, approx. 4 years
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice